These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 36074799)

  • 1. The Efficacy of Oligonol in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blinded Placebo-Controlled Trial.
    Chayanupatkul M; Sawatdee W; Chutaputti A; Tangkijvanich P
    J Integr Complement Med; 2022 Nov; 28(11):904-908. PubMed ID: 36074799
    [No Abstract]   [Full Text] [Related]  

  • 2. Litchi-Derived Polyphenol Alleviates Liver Steatosis and Gut Dysbiosis in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Double-Blinded, Placebo-Controlled Study.
    Jinato T; Chayanupatkul M; Dissayabutra T; Chutaputti A; Tangkijvanich P; Chuaypen N
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
    Lee HA; Moon H; Kim Y; Lee HA; Kim HY
    Trials; 2023 Aug; 24(1):490. PubMed ID: 37533096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study).
    Ozaki A; Yoneda M; Kessoku T; Iwaki M; Kobayashi T; Honda Y; Ogawa Y; Imajo K; Sakai E; Taguri M; Yamanaka T; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    Contemp Clin Trials Commun; 2020 Mar; 17():100516. PubMed ID: 31956725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
    Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
    Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial.
    Li N; Cui C; Xu J; Mi M; Wang J; Qin Y
    Am J Clin Nutr; 2024 Sep; 120(3):507-517. PubMed ID: 39032786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial.
    Yoneda M; Honda Y; Ogawa Y; Kessoku T; Kobayashi T; Imajo K; Ozaki A; Nogami A; Taguri M; Yamanaka T; Kirikoshi H; Iwasaki T; Kurihashi T; Saito S; Nakajima A
    BMJ Open Diabetes Res Care; 2021 Feb; 9(1):. PubMed ID: 33593749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis.
    Arulanandan A; Ang B; Bettencourt R; Hooker J; Behling C; Lin GY; Valasek MA; Ix JH; Schnabl B; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1513-20.e1. PubMed ID: 25661453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
    Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A
    Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease.
    Kessoku T; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Ogawa Y; Imajo K; Saigusa Y; Yamamoto K; Yamanaka T; Usuda H; Wada K; Yoneda M; Saito S; Nakajima A
    BMJ Open; 2020 Sep; 10(9):e037961. PubMed ID: 32907904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat with Radiofrequency Ultrasound Data Using One-dimensional Convolutional Neural Networks.
    Han A; Byra M; Heba E; Andre MP; Erdman JW; Loomba R; Sirlin CB; O'Brien WD
    Radiology; 2020 May; 295(2):342-350. PubMed ID: 32096706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
    Cusi K; Alkhouri N; Harrison SA; Fouqueray P; Moller DE; Hallakou-Bozec S; Bolze S; Grouin JM; Jeannin Megnien S; Dubourg J; Ratziu V
    Lancet Gastroenterol Hepatol; 2021 Nov; 6(11):889-902. PubMed ID: 34560015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.